To the full analysis
Buyback calculator for Crescent Biopharma
Crescent Biopharma stock: key metrics
CBIOMargins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2011 | 0.0% | −159.5% | −160.3% |
| 2012 | 100.0% | 23.8% | 24.0% |
| 2013 | 100.0% | −265.7% | −265.6% |
| 2014 | 100.0% | −74.1% | −74.0% |
| 2015 | 100.0% | −63.7% | −63.6% |
| 2016 | 0.0% | −172,505.3% | −171,945.1% |
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | no data | no data | no data |
| 2020 | 100.0% | −506.8% | −502.1% |
| 2021 | 100.0% | −5,470.7% | −5,469.0% |
| 2022 | 100.0% | −63,204.4% | −62,251.7% |
| 2023 | 100.0% | −392,752.9% | −368,994.2% |
| 2024 | no data | no data | no data |
| 2025 | 100.0% | −1,407.5% | −1,419.6% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2011 | −72.3% | −38.5% | −21.1% |
| 2012 | 29.2% | 28.8% | 19.8% |
| 2013 | −100.0% | no data | −100.0% |
| 2014 | −21.9% | −32.7% | −19.4% |
| 2015 | −31.6% | −22.1% | −26.3% |
| 2016 | −90.1% | −65.7% | −75.0% |
| 2017 | −27.8% | −34.3% | −25.9% |
| 2018 | −23.5% | −24.9% | −22.5% |
| 2019 | −35.1% | −26.7% | −32.2% |
| 2020 | −39.8% | −28.3% | −35.7% |
| 2021 | −77.7% | −47.1% | −67.2% |
| 2022 | −100.0% | −59.7% | −90.1% |
| 2023 | −96.1% | −76.2% | −81.4% |
| 2024 | 200.0% | no data | −100.0% |
| 2025 | −75.8% | no data | −64.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jan 2015)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.